Cargando…

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?

Detalles Bibliográficos
Autor principal:	Baxevanis, Constantin N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913410/ https://www.ncbi.nlm.nih.gov/pubmed/36765836 http://dx.doi.org/10.3390/cancers15030881

Ejemplares similares

Immune checkpoint inhibition in advanced esophageal squamous cell carcinoma: how can we personalise management?
por: Cagney, Hannah P., et al.
Publicado: (2023)

How We Will, Not Whether We Can: Improving Health and Healthcare
por: Zelmer, Jennifer
Publicado: (2017)

Endogenous immunity at the forefront of tumor dormancy
por: Baxevanis, Constantin N, et al.
Publicado: (2015)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Spinal anesthesia: how can we improve patient satisfaction?
por: Lee, Jong Seok
Publicado: (2010)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

Brazilian Nephrology Census 2019: a guide to assess the quality and scope of renal replacement therapy in Brazil. How are we, and how can we improve?
por: Lopes, Marcelo Barreto
Publicado: (2021)

How can we obtain truly translational mouse models to improve clinical outcomes in schizophrenia?
por: Clapcote, Steven J.
Publicado: (2022)

Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
por: Renner, Alex, et al.
Publicado: (2019)

How can we improve the use of essential evidence-based interventions?
por: Belizán, José M, et al.
Publicado: (2014)

The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't
por: Malek, Alexandre E, et al.
Publicado: (2021)

Biomarkers in the Era of Precision Oncology
por: Baxevanis, Constantin N.
Publicado: (2023)

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
por: Jordan, B., et al.
Publicado: (2021)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Li, Siqi, et al.
Publicado: (2020)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
por: Matsuo, Norikazu, et al.
Publicado: (2019)

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
por: Ettl, Tobias, et al.
Publicado: (2022)

How We Can Change Clinical Practice Using Antioxidant Molecules?
por: Favero, Gaia, et al.
Publicado: (2022)

How Can We Achieve Healthy Aging?
por: Woo, Jean
Publicado: (2017)

How can we prepare for this autumn and winter?
por: Lee, Jong-Koo
Publicado: (2021)

How Can We Afford Costly Medicines?
por: Mucklow, John C
Publicado: (2000)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

How Can We Propagate the National Endoscopy Quality Improvement Program and Improve the Quality of Endoscopic Screening?
por: Yang, Dong-Hoon
Publicado: (2016)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

How Can We Draw the Line between Clinical Care and Medical Research
Publicado: (2007)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Asthma attacks: how can we reduce the risks?
por: Thomas, Mike, et al.
Publicado: (2015)

How we can prevent a resurgence this year
por: Lee, Jong-Koo
Publicado: (2023)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy
por: Murakata, Yoshiko, et al.
Publicado: (2022)

Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
por: Zhao, Chen, et al.
Publicado: (2019)

Paediatric Surgery on the African Continent: How Far Have We Come; How Far Can We Go?
por: Numanoglu, Alp
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dof0qi9fvmako9sbj30993r7qp